GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » EV-to-Revenue

Scandion Oncology A/S (OSTO:SCOL) EV-to-Revenue : (As of Jun. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Scandion Oncology A/S's enterprise value is kr41.46 Mil. Scandion Oncology A/S's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00 Mil. Therefore, Scandion Oncology A/S's EV-to-Revenue for today is .

The historical rank and industry rank for Scandion Oncology A/S's EV-to-Revenue or its related term are showing as below:

During the past 7 years, the highest EV-to-Revenue of Scandion Oncology A/S was 4647.10. The lowest was 603.20. And the median was 1634.80.

OSTO:SCOL's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.94
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-07), Scandion Oncology A/S's stock price is kr0.498. Scandion Oncology A/S's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00. Therefore, Scandion Oncology A/S's PS Ratio for today is .


Scandion Oncology A/S EV-to-Revenue Historical Data

The historical data trend for Scandion Oncology A/S's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S EV-to-Revenue Chart

Scandion Oncology A/S Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - - - - -

Scandion Oncology A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Scandion Oncology A/S's EV-to-Revenue

For the Biotechnology subindustry, Scandion Oncology A/S's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scandion Oncology A/S's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandion Oncology A/S's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Scandion Oncology A/S's EV-to-Revenue falls into.



Scandion Oncology A/S EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Scandion Oncology A/S's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=41.457/0
=

Scandion Oncology A/S's current Enterprise Value is kr41.46 Mil.
Scandion Oncology A/S's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandion Oncology A/S  (OSTO:SCOL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Scandion Oncology A/S's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.498/0
=

Scandion Oncology A/S's share price for today is kr0.498.
Scandion Oncology A/S's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandion Oncology A/S EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Scandion Oncology A/S's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Scandion Oncology A/S (OSTO:SCOL) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines